In patients with CKD with or without T2DM, SGLT-2 inhibitors decreased the risk for all-cause mortality (HR 0.87; [95% CI 0.79–0.94]; τ2 = 0; I2 = 0%), CV death (HR 0.86; [95% CI 0.81–0.91]; τ2 = 0; I2 = 0%), and hospitalization for HF (HR 0.67; [95% CI 0.62–0.73]; τ2 = 0; I2 = 0%) (Fig 3). The gene discussed is SLC5A2; the disease is chronic kidney disease.